The pure anti-estrogen ICI, 182,780, which is presently being used to successfully treat breast cancer in the clinic [44] has little effect on ERα mRNA levels [35], promotes cofactor disassociation [45], and induces ERα protein proteasome mediated degradation [35], [46]. Here, ESR1 is linked to breast carcinoma.